MARKET

VCYT

VCYT

Veracyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.37
+1.61
+5.05%
After Hours: 33.37 0 0.00% 16:52 08/06 EDT
OPEN
32.14
PREV CLOSE
31.77
HIGH
33.62
LOW
31.80
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
36.42
52 WEEK LOW
13.90
MARKET CAP
1.69B
P/E (TTM)
-53.6754
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VCYT stock price target is 38.00 with a high estimate of 40.00 and a low estimate of 37.00.

EPS

VCYT News

More
Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
Veracyte, Inc. (Nasdaq: VCYT) announced today that data presented at the American Thoracic Society 2020 Virtual conference reinforce the potential clinical value of the company’s advanced genomic tests in diagnosing serious lung diseases. The data, presented i
Business Wire · 1d ago
Scaling Up Output of a Covid Vaccine Is Costly, Says Moderna
The biotech says it is already producing its vaccine and stockpiling it, on the assumption that it will be approved by regulators.
Barrons.com · 1d ago
Veracyte prices equity offering at $30
Veracyte (NASDAQ:VCYT) has priced its public offering of 6M common shares at $30.00/share, for expected gross proceeds of $180M. Net proceeds will be used
seekingalpha · 1d ago
Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
Veracyte announces positive clinical utility data for Percepta classifier published online in CHEST
Business Wire · 1d ago
Veracyte launches 6M-share stock offering
Veracyte (NASDAQ:VCYT) commences a public offering of 6M common shares. Underwriters' over-allotment is an additional 900K shares. Price and terms have yet
seekingalpha · 3d ago
Veracyte Announces Proposed Public Offering of 6M Shares Of Common Stock
Benzinga · 3d ago
Veracyte Announces Proposed Public Offering of Common Stock
Veracyte, Inc. (Nasdaq: VCYT) (the "Company") today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwri
Business Wire · 3d ago
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of 0.00% and 17.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 23:10

Industry

Biotechnology & Medical Research
-0.96%
Pharmaceuticals & Medical Research
-0.46%

Hot Stocks

Symbol
Price
%Change

About VCYT

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
More

Webull offers kinds of Veracyte Inc stock information, including NASDAQ:VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.